Bristol Myers Squibb (BMY) Short-term Investments (2009 - 2026)

Bristol Myers Squibb (BMY) has reported Short-term Investments for 18 consecutive years, with $2.3 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Short-term Investments rose 133.57% year-over-year to $2.3 billion in Q2 2026; TTM through Jun 2026 was $2.3 billion, a 133.57% increase from a year earlier, with the FY2025 full-year figure at $464.0 million, down 9.55% from the prior year.
• Short-term Investments was $2.3 billion for Q2 2026 at Bristol Myers Squibb, up from $912.0 million in the prior quarter.
• Over five years, Short-term Investments peaked at $2.6 billion in Q1 2022 and troughed at $130.0 million in Q4 2022.
• A 5-year average of $885.8 million and a median of $644.5 million in 2024 frame the typical range for Short-term Investments.
• Across the five-year window, Short-term Investments slumped 95.65% in 2022 and jumped 527.69% in 2023, its largest moves.
• Over 5 years, Short-term Investments stood at $130.0 million in 2022, then jumped by 527.69% to $816.0 million in 2023, then sank by 37.13% to $513.0 million in 2024, then fell by 9.55% to $464.0 million in 2025, then soared by 405.39% to $2.3 billion in 2026.
• The last three Short-term Investments figures came in at $2.3 billion (Q2 2026), $912.0 million (Q1 2026), and $464.0 million (Q4 2025), per Business Quant data.